Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 315Lymphoma 282Leukemia 227Precursor Cell Lymphoblastic Leukemia-Lymphoma 216Lymphoma, Non-Hodgkin 178Leukemia, Lymphocytic, Chronic, B-Cell 177Multiple Myeloma 174Lymphoma, Large B-Cell, Diffuse 174Lymphoma, Follicular 142Leukemia, Myeloid, Acute 136Lymphoma, Mantle-Cell 126Hodgkin Disease 125Burkitt Lymphoma 118Myelodysplastic Syndromes 110Lymphoma, Large-Cell, Immunoblastic 89Lymphoma, B-Cell, Marginal Zone 85Recurrence 67Neoplasms, Plasma Cell 62Leukemia, Myeloid, Chronic-Phase 59Neuroblastoma 56Dendritic Cell Sarcoma, Interdigitating 56Leukemia, Myeloid, Accelerated Phase 55Myeloproliferative Disorders 54Melanoma 54Congenital Abnormalities 48Neoplasms 47Leukemia, Myelomonocytic, Chronic 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Blast Crisis 45Lymphoma, Large-Cell, Anaplastic 44

Interventions

Transplantation Conditioning 1Thiotepa 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × High Risk Myeloid Malignancies × Cyclophosphamide × Clear all
NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡